Salud financiera de hoja de balance de Bioceres Crop Solutions
Salud financiera controles de criterios 3/6
Bioceres Crop Solutions tiene un patrimonio de los accionistas total de $106.6M y una deuda total de $228.6M, lo que sitúa su ratio deuda-patrimonio en 214.4%. Sus activos y pasivos totales son $560.4M y $453.7M respectivamente.
Información clave
214.39%
Ratio deuda-patrimonio
US$228.57m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$11.06m |
| Patrimonio | US$106.62m |
| Total pasivo | US$453.75m |
| Activos totales | US$560.36m |
Actualizaciones recientes sobre salud financiera
Artículo de análisis • Nov 17
Is Bioceres Crop Solutions (NASDAQ:BIOX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Jul 22
Bioceres Crop Solutions (NASDAQ:BIOX) Use Of Debt Could Be Considered Risky
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Apr 04
Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Aug 03
These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Artículo de análisis • Feb 03
Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Recent updates
Artículo de análisis • Feb 10
Investors Don't See Light At End Of Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Tunnel And Push Stock Down 54%
To the annoyance of some shareholders, Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) shares are down a considerable 54...
Actualización del análisis • Dec 17
BIOX: Portfolio Recapitalization Progress Will Eventually Overcome Argentina Liquidity Headwinds
Analysts have trimmed their price target on Bioceres Crop Solutions by roughly $0.10 per share, citing heightened Argentina-related liquidity volatility and increased uncertainty around the company’s portfolio recapitalization efforts. Analyst Commentary Analysts acknowledge that Bioceres retains a differentiated portfolio and strategic exposure to key agricultural markets, but sentiment has turned more cautious as near term risks have become more prominent in their valuation work.Actualización del análisis • Dec 03
BIOX: Next Generation Product Pipeline Will Offset Argentina Liquidity Pressures
Analysts have trimmed their price target on Bioceres Crop Solutions to around $2.25 from approximately $3.63, reflecting concerns over Argentina related liquidity pressures and portfolio recapitalization challenges, even as they continue to see long term value in the company’s next generation product pipeline. Analyst Commentary Street research on Bioceres Crop Solutions reflects a mixed backdrop, with liquidity concerns and execution risks in Argentina offset by continued confidence in the long term earnings power of its next generation product portfolio.Actualización del análisis • Nov 19
BIOX: Portfolio Recapitalization Will Overcome Argentina Liquidity Pressure Ahead
The analyst price target for Bioceres Crop Solutions was revised downward from $3.75 to $3.63. Analysts cited increased pressure from liquidity concerns and recent portfolio challenges as key factors for the adjustment.Artículo de análisis • Nov 17
Is Bioceres Crop Solutions (NASDAQ:BIOX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Actualización del análisis • Nov 02
BIOX: Recovery From Argentina Volatility Will Drive Future Upside Potential
Analysts have lowered their fair value price target for Bioceres Crop Solutions from $4.17 to $3.75 per share. They cite concerns about Argentina's economic volatility, recent earnings shortfalls, and increased hurdles to the company's portfolio strategy.Artículo de análisis • Oct 30
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) shareholders are no doubt pleased to see that the share price has bounced...Actualización del análisis • Oct 18
Transition To Capital-Light Model And Global Expansion Will Shape Future Success
Analysts have revised their price target for Bioceres Crop Solutions downward from $8 to $5, citing weaker-than-expected Q4 results and leadership transitions. However, they continue to highlight potential in the company’s pipeline for future value creation.Actualización del análisis • Oct 04
Transition To Capital-Light Model And Global Expansion Will Shape Future Success
Analysts have lowered their price target for Bioceres Crop Solutions from $8 to $5, citing weaker-than-expected Q4 results and concerns over executive turnover. However, they continue to see long-term value in the company's innovation pipeline.Artículo de análisis • Sep 15
The Market Doesn't Like What It Sees From Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Revenues Yet As Shares Tumble 31%
Unfortunately for some shareholders, the Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) share price has dived 31% in the...Seeking Alpha • Sep 09
Bioceres Crop Solutions: Waiting For Gross Profit To Turn (Downgrade)
Summary Downgrade Bioceres Crop Solutions Corp. to Hold due to Argentina's volatile currency, credit constraints, and a challenging shift in the seed sales model. Recent results show sharply lower revenues, deeper losses, but disciplined cash management, and a focus on cost reductions going forward. Valuation sits at 3.5x gross profit and 8.5–11x EV/EBITDA, but earnings risk and potential dilution remain high. If cost cuts and inventory normalization drive EBITDA recovery, I may reconsider BIOX stock, but for now, patience is warranted. Read the full article on Seeking AlphaArtículo de análisis • Aug 01
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Not Doing Enough For Some Investors As Its Shares Slump 25%
The Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) share price has fared very poorly over the last month, falling by a...Artículo de análisis • Jul 22
Bioceres Crop Solutions (NASDAQ:BIOX) Use Of Debt Could Be Considered Risky
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Apr 04
Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Mar 07
Bioceres Crop Solutions' (NASDAQ:BIOX) Weak Earnings May Only Reveal A Part Of The Whole Picture
Last week's earnings announcement from Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) was disappointing to investors...Artículo de análisis • Mar 05
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Might Not Be As Mispriced As It Looks After Plunging 41%
The Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Feb 13
Bioceres Is Approaching Distressed Prices, But I Remain On The Sidelines
Summary Bioceres Crop Solutions Corp. reported a disappointing Q2 2025 with revenues down 24%, driven by Argentina's economic crisis, despite improved international sales. BIOX stock is down 62% year-over-year, and I maintain a Hold rating due to concerns about the company's ability to turn around. The shift to a licensing model for HB4 technology and R&D cuts may improve short-term finances but pose long-term risks. Despite a lower valuation, Bioceres' financial risks and management's past decisions make it unattractive until more data on turnaround effectiveness is available. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Bioceres Is Getting Cheaper, Not Yet An Opportunity But More Interesting
Summary Bioceres' 1Q25 results were challenging due to adverse weather in Argentina, affecting crop nutrition, protection, and seeds, but potential recovery is expected in 2Q25. BIOX has depreciated significantly, now trading at $6.7 per share, with a market cap of $400 million, making it a more interesting Hold. Despite some improvements, HB4 commercialization remains underwhelming, and financial risks persist, warranting caution before investing in potential developments. Valuation is approaching reasonable levels, but the company's execution, financial risk, and lack of clear reporting keep me on the sidelines for now. Read the full article on Seeking AlphaArtículo de análisis • Sep 28
Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper
Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) shareholders that were waiting for something to happen have been dealt a...
Nuevo análisis • Sep 18
HB4 Wheat's US Approval Sparks Global Expansion And Profit Growth Surge
Approval of HB4 Wheat in the US highlights significant expansion and revenue opportunities, enhancing global acceptance and credibility of HB4 technology.Seeking Alpha • Sep 17
Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices
Summary Bioceres' 4Q24 results disappointed, with flat profitability and a 15% stock drop, driven by a bear market in agricultural commodities and commercialization challenges for HB4 products. The company's debt rose, particularly short term, with unclear maturity risks, and profitability challenges persisted despite top-line growth. Bioceres is shifting tactics for HB4, reducing the priority of its identity-protected program to manage working capital and focusing more on its bio solutions segment. Given low earnings yields, high debt, and market volatility, I rate Bioceres as a Hold, doubting its ability to achieve necessary growth for fair valuation. Read the full article on Seeking AlphaArtículo de análisis • Aug 03
These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Mar 23
Bioceres Needs To Add Clarity Around Borrowings
Summary Bioceres is an agricultural supply company with growth potential in seed genetics and biopesticides markets. The company's 2Q24 results showed revenue growth and stable cost structure, leading to profitability. These were expected, given the Argentinian drought in 2023. Concerns remain about the company's high debt maturities and lack of clarity on its debt and refinancing plans. The company's valuation is that of a high growth company, and yet Bioceres is not showing a growth trend. Read the full article on Seeking AlphaArtículo de análisis • Feb 03
Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Oct 04
Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Jun 21
Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear
Bioceres Crop Solutions Corp.'s ( NASDAQ:BIOX ) price-to-sales (or "P/S") ratio of 2x may not look like an appealing...Artículo de análisis • May 09
Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Sep 06
Bioceres: A Resilient Small Cap With Conference Appearances After Thursday's Earnings
Summary Corporate conference season is underway, and one Chemicals company is expected to speak at three events through mid-November. Bioceres Crop Solutions also has an earnings release due out Thursday morning, which should move shares in the near term. The stock has been a strong outperformer this year but has a mixed earnings history. I look to clues from the options market on where the stock might go. It is conference season on Wall Street. Investors must pay close attention to corporate events that might impact the stocks they own. One Materials sector company, a small cap, features three potentially market-moving conferences/forums at which the firm's management team is expected to speak. Often at these gatherings, fresh industry news and trends are presented along with key updates on individual companies. The Materials sector is particularly interesting right now given a slew of macro headwinds impacting both domestic and foreign firms. Weather-related trends are also constantly in the news this summer. One Argentina-based Chemicals stock has been resilient in the face of so much uncertainty from interest rates to currencies to climate change. According to CFRA Research, Bioceres Crop Solutions Corp. (BIOX), together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The $846 million market cap Argentina-based Chemicals company in the Materials sector has slightly negative GAAP earnings over the past 12 months and does not pay a dividend, according to The Wall Street Journal. On valuation, earnings are seen as rising this year and next, according to CFRA's forecast. Assuming $0.55 of EPS next year, the stock trades at a high 25-times forward earnings multiple. On a price-to-sales ratio basis, the value is not as high: just 2.3x. For context, according to Koyfin Charts, Bioceres' price-to-sales ratio peaked near 3.0x in mid-2021 with a low of 0.8x in late 2019. Bioceres: Earnings Outlook CFRA BIOX: Historical Price-To-Sales Ratio Trend Koyfin Charts Looking ahead, Wall Street Horizon's data show three events that could influence BIOX shares over the coming two-plus months. Credit Suisse 35th Annual Specialties & Basics Conference 2022: Sept 13-14 Lake Street Capital Markets 6th Annual Best Ideas Growth Conference 2022: Sept 14 S&P Global Crop Science Forum 2022: Nov. 10 There's also a critical Q4 2022 earnings date before the open on Thursday of this week, with an earnings call immediately after results are released. Investors can listen live here. Corporate Event Calendar: Earnings & Conferences Provide Volatility Catalysts Wall Street Horizon The Options AngleSeeking Alpha • Aug 23
Bioceres Crop Solutions jumps 15% after investor pitch
Bioceres Crop Solutions (NASDAQ:BIOX) soared 15% in after hours trading after an investor was bullish on the agriculture company. Bioceres (BIOX) "is a company that I think is going to be the future green Monsanto," Ospraie Management founder and managing partner Dwight Anderson said in an interview with CNBC. "There revenues are exploding. They are exactly in the right position in terms of their customer base and distribution and environmentally friendly products." He expects Bioceres (BIOX) shares may be 2x or 3x higher in the next two years. Ospraie Management is the third largest holder of Bioceres with a 10% stake. Bioceres (BIOX) is scheduled to report fiscal Q4 results on Sept. 8.Artículo de análisis • Apr 10
We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Mar 31
Bioceres Has Not Resolved Its Major Risks And Is Growing Based On Commodities Bullishness
Bioceres has a profitable segment based on its subsidiary Rizobacter, that sells adjuvants, micro beaded fertilizers and other agricultural solutions. Rizobacter's profits are growing significantly aided by the bull market in agricultural commodities. Bioceres uses Rizobacter's profits and debt to fund its growth strategy based on HB4 technology and further acquisitions. The problem is that HB4's market is difficult to estimate. To increase risk, a high level of debt puts Bioceres in a difficult situation if commodities prices recede. Bioceres continues in the same vein with the proposal to merge with Marrone Bio Innovations.Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($294.3M) de BIOX no cubren sus pasivos a corto plazo ($328.6M).
Pasivo a largo plazo: Los activos a corto plazo de BIOX ($294.3M) superan a sus pasivos a largo plazo ($125.1M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de BIOX (204%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de BIOX ha crecido de 211.5% a 214.4% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: Aunque no es rentable BIOX tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.
Pronóstico de cash runway: BIOX no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 33.7% al año.
Descubre empresas con salud financiera
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/07 21:16 |
| Precio de las acciones al final del día | 2026/05/07 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/06/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Bioceres Crop Solutions Corp. está cubierta por 2 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Austin Moeller | Canaccord Genuity |